MERREM Drug Patent Profile
✉ Email this page to a colleague
When do Merrem patents expire, and what generic alternatives are available?
Merrem is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in MERREM is meropenem. There are thirty-two drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the meropenem profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Merrem
A generic version of MERREM was approved as meropenem by ACS DOBFAR on October 26th, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MERREM?
- What are the global sales for MERREM?
- What is Average Wholesale Price for MERREM?
Summary for MERREM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 84 |
| Clinical Trials: | 15 |
| Patent Applications: | 5,317 |
| Drug Prices: | Drug price information for MERREM |
| What excipients (inactive ingredients) are in MERREM? | MERREM excipients list |
| DailyMed Link: | MERREM at DailyMed |
Recent Clinical Trials for MERREM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Wake Forest University Health Sciences | Phase 4 |
| Johns Hopkins University | Phase 2 |
| Hoffmann-La Roche | Phase 1 |
US Patents and Regulatory Information for MERREM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | MERREM | meropenem | INJECTABLE;INJECTION | 050706-001 | Jun 21, 1996 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | MERREM | meropenem | INJECTABLE;INJECTION | 050706-003 | Jun 21, 1996 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MERREM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | MERREM | meropenem | INJECTABLE;INJECTION | 050706-001 | Jun 21, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | MERREM | meropenem | INJECTABLE;INJECTION | 050706-003 | Jun 21, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MERREM
See the table below for patents covering MERREM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Netherlands | 950019 | ⤷ Sign Up | |
| Japan | H0466872 | ⤷ Sign Up | |
| Japan | H0551594 | ⤷ Sign Up | |
| Japan | S601186 | NOVEL BETA-LACTAM COMPOUND AND ITS PREPARATION | ⤷ Sign Up |
| Austria | 121402 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MERREM
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3412676 | PA2020519,C3412676 | Lithuania | ⤷ Sign Up | PRODUCT NAME: VABORBAKTAMO IR (ARBA) JO DRUSKOS, IR (ARBA) HIDRATO BEI MEROPENEMO IR (ARBA) JO DRUSKOS, IR (ARBA) HIDRATO, YPAC MEROPENEMO TRIHIDRATO, DERINYS; REGISTRATION NO/DATE: EU/1/18/1334 20181120 |
| 2603514 | 2019014 | Norway | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF VABORBACTAM, AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE; REG. NO/DATE: EU/1/18/1334/001 20181122 |
| 2603514 | 1990017-4 | Sweden | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF VABORBACTAM AND/OR SALT OR HYDRATE THEREOF, AND MEROPENEM AND/OR A SALT HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE.; REG. NO/DATE: EU/1/18/1334 20181122 |
| 0126587 | SPC/GB95/030 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MEROPENEM OPTIONALLY IN THE FORM OF A HYDRATE AND /OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: IT 99/1994 19940817; UK 12619/0097 19950119; UK 12619/0098 19950119; UK 12619/0099 19950119; UK 12619/0100 19950119 |
| 2603514 | SPC/GB19/021 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: VABORBACTAM, AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE.; REGISTERED: UK EU/1/18/1334 (NI) 20181120; UK PLGB 16239/0061 20181120 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
